Phase 1 study of bicalutamide, an androgen receptor inhibitor.

This trial investigates whether daily oral bicalutamide combined with brain re-irradiation is safe for patients with recurrent high-grade glioma or glioblastoma. Conducted at the University of Nebraska, the dose-escalation study aims to determine the maximum tolerated dose over a six‐month treatment period.